Development & manufacture - drug delivery devices

Recipharm offers pharmaceutical contract development and manufacturing of large commercial batch sizes of tablets, capsules or powders. 

Recipharm work with: • General APIs as well as some special substances • Conventional technologies, including fluid...

We keep both the end-user and our pharmaceutical partners at the forefront of our product design, producing injection devices created to facilitate patient-friendly administration and overcome formulation challenges, particularly for high viscosity formulations.

At Recipharm we deliver market-leading design, development, and manufacturing services for nasal spray devices to the global pharmaceutical market.

Deliver precise and effective treatments to your patients by partnering with Recipharm for your pMDI products. Backed by over 60 years of experience, we have overcome many pMDI product development challenges to provide you with high quality products.

The Resyca soft mist inhaler is a joint venture between Recipharm and Medspray and uses proprietary spray nozzle technology to deliver next-generation SMIs that deliver an aerosol from a liquid solution.

Recipharm offer formulation development services for all dosage forms. We develop everything from simple formulations for early studies to more complex formulations suited for commercialisation.

An integrated service for inhalation drug products and devices spanning early-stage development to commercial manufacture. Our depth of knowledge means we can overcome the challenges associated with inhalation drug products and devices.

At Recipharm, we offer drug product development services for all common dosage forms. Our team can manage the complexity of your project, helping you find the best solution whether you are looking for development support to take your product to first-in-human (FIH) studies or to advance your product to mar...

Recipharm has more than 25 years’ experience in drug substance development and manufacturing. We are ideally placed to deliver a wide range of drug substance services from our dedicated development facilities around the world.

Recipharm  have committed to invest in and fully implement the technical solutions needed to comply with global requirements for pharmaceutical serialisation and track and trace. Our serialisation offering includes: • Experience in already providing serialised products to Turkey, Korea and China • Se...

Recipharm have more than 20 years experience supplying clinical trial material to our clients. Our development facilities cater for a range of clinical trials from preclincal to smaller Phase III trials. We also offer commercial manufacturing for very large clinical batches.

In this written panel discussion experts in manufacturing in the pharmaceutical supply chain comment on the manufacturing landscape, how sustainable practices are being incorporated more readily, the challenges associated with this and the overall advantages. 

Your innovative drug. Our world-class production facilities. Discover the genius of working together.

Recipharm receives regulatory approval for the manufacture of a microbiome-based product for the prevention of Clostridioides difficile recurrent infection, under GenIbet Biopharmaceuticals and Seres Therapeutics. 

We are approaching the end of a year which saw global vaccine rollout for COVID-19, 44 novel drug approvals (to date) and the return of the CPHI Worldwide in-person event.

Lyophilisation or freeze drying is an important means to improve thermal stability of a drug product, according to Thomas Becker, Quality Director and Qualified Person, Recipharm. This is particularly true for those that are thermolabile, such as mRNA vaccine candidates.

A summary exploring Recipharm’s key considerations when it comes to developing effective analytical methods for drug projects.

With so many outsourcing options available, selecting the CDMO that is the right fit for any particular sponsor company can be a challenging task.

In January 2020 the European Commission published some proposed significant revisions to Annex 1, the EU’s good manufacturing practice (GMP) guide for the manufacture of sterile products. In the following three-month consultation period, affected organisations and stakeholders from over 70 different countries submitted more than 2,000 comments to the proposed update.

Sponsors within the biopharmaceutical industry are increasingly turning to outsourcing for several reasons; remaining competitive and flexible within a quickly evolving sector, gaining access to manufacturing capacity and state-of-the-art equipment and scaling up to the commercial level are just three examples.

In January 2020 the European Commission published some proposed significant revisions to Annex 1, the EU’s good manufacturing practice (GMP) guide for the manufacture of sterile products. In the following three-month consultation period, affected organisations and stakeholders from over 70 different countries submitted more than 2,000 comments to the proposed update.